FDA Approves Eflornithine for Children, Adults With High-Risk Neuroblastoma
December 14th 2023Eflornithine (Iwilfin) received FDA approval to reduce the risk for relapse in pediatric and adult patients with high-risk neuroblastoma, making it the first therapy to reduce risk for relapse in children with the disease.
New Companion Diagnostic Is Approved to Aid In Gastric Cancer Decision Making
November 15th 2023The PD-L1 IHC 22C3 pharmDx diagnostic tool will help identify patients with gastric or gastroesophageal junction adenocarcinoma whose disease expresses PD-L1 and who are thereby eligible for pembrolizumab.